Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria

Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria

Copyright © 2023 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 247(2023) vom: 01. Feb., Seite 109247
1. Verfasser: Wang, Jiaqi (VerfasserIn)
Weitere Verfasser: He, Liting, Yi, Wanyu, Liang, Qing, Jiang, Li, Tan, Yixin, Zhang, Guiying, Su, Yuwen, Xiao, Rong, Lu, Qianjin, Long, Hai
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Autoimmunity Autologous serum skin test (ASST) Chronic spontaneous urticaria (CSU) Interleukin-2 (IL-2) Urticaria control test (UCT) Weekly urticaria activity score (UAS7) Interleukin-2 Histamine Antagonists
Beschreibung
Zusammenfassung:Copyright © 2023 Elsevier Inc. All rights reserved.
PURPOSE: To describe the effectiveness and tolerability of low-dose interleukin (IL)-2 in treating patients with chronic spontaneous urticaria (CSU) refractory to H1-antihistamines
METHODS: This retrospective study included CSU patients who received treatment with at least one cycle of IL-2, injected intramuscularly at a dose of 1.0 million international units daily for 7 consecutive days, after failing treatment with H1-antihistamines. Patients were followed up for ≥12 weeks
RESULTS: Of the 15 patients, 7 (46.7%) and 11 (73.3%) achieved complete response at Week 2 and Week 12, respectively. The mean change of urticaria control test (UCT) and weekly urticaria activity score (UAS7) from baseline was 6.6 (95% CI, 4.2 to 8.9) and - 16.9 (95% CI, -24.0 to -9.8), respectively, at Week 12. Local injection-site reactions were the most common adverse events. No serious adverse events were reported
CONCLUSION: Low-dose IL-2 treatment improves symptoms and disease control for CSU patients refractory to H1-antihistamines
Beschreibung:Date Completed 14.02.2023
Date Revised 18.03.2023
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2023.109247